We thank Inokuchi et al. 1 for their detailed comments regarding our letter 2 and appreciate the opportunity to reply. Firstly, we would like to emphasize that Inokuchi et al. performed an extensive analysis of the c-kit variants M541L and N564K, analysing clinical data from 80 patients suffering from CML and using a murine system for in vitro studies. 3 In contrast, our data might be indeed limited, yet still powerful. The limitation reflects solely our aim of testing the hypothesis of whether or not the variants M541L and N564K are associated with CML in a Caucasian populations. Equal allele frequencies for 541 Leu in 102 Caucasian CML patients and 166 controls (8.3 and 8.1%, respectively) and lack of the 564 Lys sequence variant in all patients and controls do not support a functional importance for either variant in CML. This finding is corroborated by the low degree of conservation in various species and the data from the Sorting Intolerant From Tolerant amino-acid substitutions (SIFT) analysis, which predicted that both amino-acid changes are tolerable and therefore do not affect the function of the protein. 2 We agree with Inokuchi et al.
1 that ethnic differences in the allele frequencies of common sequence variations may be associated with different phenotypes, which we have observed previously, 4, 5 although the reason for these differences is unknown. We cannot exclude that the same may apply for Japanese CML patients carrying c-kit variants.
However, we are unable to satisfy the request by Inokuchi et al. regarding the comparison of clinical and hematological data from our 16 CML patients and 26 healthy controls carrying the M541L variant with those of our wild-type c-kit patients and controls for two main reasons: Firstly, haematological data from our anonymous controls are not available, but frequent screening of our blood donors by means of a questionnaire, RBC and WBC counts, and liver function tests would have identified those with haematological malignancies. Secondly, if univariate analysis identifies an association among variables, it is necessary to control for potential interactions among those which require a multivariate analysis. As shown by Inokuchi et al., there is great clinical and molecular heterogeneity among their seven patients carrying the M541L or N564K variants, concerning age of disease onset, chromosomal abnormalities, WBC count, platelet count, bcr-abl type, survival, giant splenomegaly and even therapy modality. 3 Due to a similar heterogeneity and a still relative low number of our patients, we will abstain from this test due to the unfeasibility of fulfilling the requirements for a meaningful statistical analysis.
Irrespective of the possibility of marginal changes in the function of c-kit harbouring 541
Leu or 564 Lys , we do not concur that the data by Inokuchi et al.
3 support this hypothesis. Furthermore, our data 2 suggest that the M541L is not associated with CML in Caucasians. As a consequence of both studies, 2,3 a prospective study of the phenotype associated with this variant in large, homogeneous Japanese and Caucasian CML populations might be warranted. Letters to the Editor with active disease in comparison to normal controls or patients in remission. 3 However, MVD can only be measured in the very limited area of the bone marrow needle biopsy specimen and is unable to assess global or in vivo tumor angiogenesis. The functional status of the blood vessel (e.g. permeability) could not be determined by MVD. Moreover, MVD cannot determine whether a particular therapeutic compound is primarily directed against the angiogenic response of the tumor. 4 Thus, the needs of a rapid and effective angiodiagnostic imaging to establish antiangiogenic drug dosage or monitor treatment response is important.
Dynamic contrast-enhanced magnetic resonance imaging (dMRI) techniques allow quantification of blood perfusion and also provide information on the functional status of the blood vessels, including blood flow and vascular permeability. 5 Increased angiogenesis of the bone marrow was detected by dMRI in patients with multiple myeloma and myelodysplastic syndrome. 6 Tumor angiogenesis imaging assessment in AML patients has not been reported. In this study, we developed an algorithm for dMRI to evaluate and visualize the in vivo tumor angiogenesis in patients with newly diagnosed acute myeloid leukemia (AML) and correlated it with clinical outcome.
From December 2001 to April 2003, a total of 17 adult patients with newly diagnosed AML were enrolled. The median age was 37 years (range: 18-74 years). In total, 17 age and gender matched normal volunteers were used as control. Every patient received bone marrow examination (aspiration/core biopsy) from the iliac crest. Diagnosis and classification of AML were made according to the French-American-British (FAB) criteria. All patients received dMRI (median of 1 day, range: 0-2 days) before induction chemotherapy of Idarubicin 12 mg/m 2 per day on days 1-3 and cytosine arabinoside (Ara-C) 100 mg/ m 2 per day on days 1-7. After complete remission (CR) was achieved, the patients received consolidation chemotherapy with either the same regimen as that of induction chemotherapy or high-dose Ara-C. All patients were followed up to March 2005. A total of 15 patients (88%) obtained a CR and eight (47%) remained disease free.
MR imaging of the spine was performed in every AML patient and normal control with a 1.5-T superconducting system (Magnetom Vision Plus; Siemens, Erlangen, Germany). A phase-array spine-coil was used and dMRI study was performed (section thickness, 10 mm; field of view, 28 cm) at the midsagittal plane of the vertebral bodies from T11 through the sacrum as described in our previously studies. 7 An injection of 0.1 mmol/kg body weight of gadopentetate dimeglumine (Magnevist; Schering, Berlin, Germany) was administrated by the power injector through a 21-gauge intravenous catheter in the right antecubital vein. A constant injection rate of 2.0 ml/s was used. Dynamic scanning was started when the injection of the contrast material commenced. The pulse sequence for the dynamic scanning used was a turbo fast low-grade shot gradient-echo sequence (8.5/4.0; prepulse inversion time, 160 ms; flip angle, 101; acquisition matrix, 72 Â 128). In total, 100 dynamic images were obtained at one frame per second for 100 s in each subject.
Signal intensity values were measured in an operator-defined region of interests (ROIs) by the radiologist, covering the entire vertebral body. The signal intensity values derived from the ROI were then plotted against time to obtain a time-signal intensity curve (Figure 1a) . The baseline value for signal intensity (SI base ) on a time-signal intensity curve was defined as the mean signal intensity from the first three images. The maximum signal intensity (SI max ) was defined as the maximum value of the rapidly rising part or first pass of the time-signal intensity curve.
After the peak, which usually occurred about 40 s after the start of injection, the time-signal intensity curve entered an equilibrium phase that lasted about 30 s. 7 For the semiquantitative analysis, the peak enhancement ratio (peak) was calculated for each ROI as (SI max ÀSI base )/SI base and initial Time-intensity curve and color-coded bone marrow blood flow and perfusion images of AML patient and normal control. (a) Time-intensity curve from the lumbar vertebral dMRI. (b, c) Colorcoded bone marrow blood flow and tissue perfusion images of AML patient and normal control. The blood flow image was the mapping for initial enhancement slope of one segment of vertebral body at early increment phase. The tissue perfusion image was the mapping for peak enhancement ratio at the mid-equilibrium phase. Obvious difference could be identified between them by the visualization of angiogenesis map.
Letters to the Editor maximum enhancement slope (slope) was measured as the most steep uprising slope from the first pass, rapid-rising part of time intensity curve. The peak indicated the concentration of contrast material in the intravascular and extravascular interstitial space and represented as the tissue perfusion of bone marrow. The slope was most influenced by the MVD within the tissue and reflected the blood flow of bone marrow. We measured the peak and slope of vertebral bodies from L1 to L5 of lumbar spine and took the average to represent as the personalized marrow angiogenesis. 
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For visualization of the angiogenesis map of bone marrow, we developed an easy to use computer program for color-coding map of the dMRI parameters. The computer program uses stateof-the-art information technologies to develop a comprehensive test-bed. Its software architecture has several layers, including an interface layer to visualize images, an analysis layer to compute statistical data, a graphics processing layer to convert image format, and an I/O layer to retrieve/store information. The interface layer uses several subwindows to enable image visualization, show statistical analysis as line chairs, and adjust parameters in an auxiliary interface.
Patient characteristics were compared using the MannWhitney U test. Cut points for high bone marrow blood flow (slope) or tissue perfusion (peak) group versus low bone marrow blood flow (slope) or tissue perfusion (peak) group of patients were determined by the Classification and Regression Tree (CART) method. CART is a nonparametric regression method that uses the recursive partitioning method to build a decision tree structure and classifies subjects into high-and low groups. Survivals were calculated using the Kaplan-Meier method and compared by the Log-rank test. The data were analyzed using STATISTICA Data Miner software (version 6.0; StatSoft Inc., Tulsa, OK, USA) and MINITAB software (release 13; Minitab Inc., State College, PA, USA).
Bone marrow angiogenesis in AML patients was significantly higher than normal controls as measured by tissue perfusion Bone marrow angiogenesis and Kaplan-Meier survival curve of AML patients. Two patients who did not achieve complete remission were also excluded from the disease-free survival analysis. For (e) and (f), the low angiogenesis group was defined as tissue perfusionp1.79 and blood flowp1.90; high angiogenesis group as tissue perfusion41.79 and blood flow41.90. Two patients with either high bone marrow tissue perfusion (peak) or high blood flow (slope), but did not have both high bone marrow blood flow (slope) and high tissue perfusion (peak), were excluded from the analysis.
(peak of AML 2.0470.69 (mean7s.d.) versus peak of control 0.4270.21) (Po0.001) and blood flow (slope of AML 2.4171.15 versus slope of control 0.8770.53) (Po0.001). The time-intensity curve derived from dMRI of lumbar spine was shown in Figure 1a . Color-coded angiogenesis map of bone marrow blood flow and tissue perfusion of one vertebral bone marrow in AML patient and normal control were shown in Figure 1b and c. The dMRI time-intensity curve and color-coded bone marrow blood flow (slope) and tissue perfusion (peak) images in two representative patients were shown in Figures 2  and 3 .
The cut-point for high versus low bone marrow tissue perfusion (peak) was set at 1.79 and for blood flow (slope) at 1.90 as determined by the CART analysis. AML patients with high bone marrow tissue perfusion (peak41.79) or high blood flow (slope41.90) had decreased disease-free survival (DFS) and overall survival (OS) compared to patients with low bone marrow tissue perfusion (peak) or blood flow (slope) as shown in Figure 4a -d. AML patients with high tumor angiogenesis as indicated by both high bone marrow blood flow (slope) and high tissue perfusion (peak) had significantly decreased DFS (P ¼ 0.03) and OS (P ¼ 0.03) as compared to the patients with low tumor angiogenesis (Figures 4e and f) . AML patients (83%) with low tumor angiogenesis remained disease free at 36 months compared to 13% of the patients with high tumor angiogenesis. In total, 83% of AML patients with low tumor angiogenesis remained alive at 40 months compared to 15% of the patients with high tumor angiogenesis. This is the first report of functional MR imaging of tumor angiogenesis in AML. Our findings that bone marrow angiogenesis is increased in newly diagnosed AML patients and increased bone marrow blood flow and tissue perfusion can predict adverse clinical outcome of AML patients, confirm that angiogenesis may play an important role in the pathogenesis of AML. 3 There is increasing evidence that AML may be an angiogenesis-dependent disease with progressive recruitment of blood vessels in the bone marrow. 3 Current surrogate markers of angiogenesis can only partially reflect the angiogenesis of hematological malignancies. dMRI may be a better alternative than MVD in bone marrow biopsy specimen because it is noninvasive and can evaluate much bigger bone marrow volumes. 8 Functional imaging of tumor angiogenesis by dMRI may have a special role in the assessment of bone marrow angiogenesis, predicting the clinical outcome, selection of antiangiogenic therapy or monitoring of response to treatment in AML. dMRI can provide noninvasive, convenient, reproducible serial evaluations of global bone marrow angiogenesis diagnostics with only 100 s' scanning time and total preparation time less than 15 min. A prospective study using repeated dMRI to monitor the tumor angiogenesis before and after treatment in AML patients is currently ongoing in our institution. The real significance of dMRI tumor-angiogenesis parameters as independent prognostic factors in AML or their interaction with other known prognostic factors in AML may need future large clinical investigations. dMRI measurements of bone marrow blood flow and tissue perfusion, which integrated the total blood vessel density and vasculature functional status (permeability) reported in this study may give a more informative evaluation of global bone marrow angiodiagnosis in AML. In the bone marrow, the enhancement of contrasts is influenced by concentration of contrast agent in the macrovascular (for example, from paired segmental arteries to intravertebral small arteriole), microvascular (from arterial capillary to sinusoid) factors, and also the extravascular or interstitial compartments. Mainly tissue microvascularization and perfusion determine the first pass or rapid-rising part (washin phase). After the first pass, capillary permeability and interstitial space components contribute to the characteristics of the curve and then yield a further increase, a plateau or an early wash out phase. As shown in the Figures 1a, 2a and 3a , the rapid-rising part or first pass in the time-intensity curve (from the point at SI base to SI max ) represented the flushing in of the contrast medium from the arterial capillaries into the extracellular space of the bone marrow cavity within the vertebral body.
The peak enhancement ratio (represents tissue perfusion in this study) has to be regarded as a complex process, including blood inflow, outflow, transit and permeability factors that affect gadolinium concentration at extracellular compartment, reflecting the summation of vessel density and permeability factors. The initial enhancement slope (represents blood flow) was the maximum slope during the initial uprising part of the timeintensity curve and would be most influenced by the MVD within the tissue. The measurements of bone marrow blood flow and perfusion using this dMRI method are practical and reproducible in our previous clinical studies. 7 For better visualization of the angiogenesis map, we develop a Webbased system, which will enable multiple users to use our tool simultaneously from remote computers. The color image presentation of tumor angiogenesis in AML patients by dMRI is easily interpretable by physicians compared to standard MRI time-intensity curves or data.
In conclusion, bone marrow angiogenesis is increased in AML patients as measured by dMRI. Increased bone marrow angiogenesis can predict adverse clinical outcome in AML. Functional MR imaging of tumor angiogenesis may help to identify the best candidate patients for tailored antiangiogenic therapy and monitor treatment response.
Chemotherapy-induced mitochondrial DNA (mtDNA) alterations are well known in patients treated for viral infections with nucleoside analogue reverse transcriptase inhibitors. 1 It is also hypothesized that certain chemotherapeutic agents for treatment of cancer may cause mtDNA mutations in vitro.
2,3 A study by Wardell et al. reported mtDNA mutations after chemotherapy and irradiation several years after the end of therapy. Although an increase in mtDNA mutations was observed in this study, the level of heteroplasmy (a mixture of mutated and normal mtDNA molecules in one cell) was usually below 2%. 4 The mitochondrion contains multiple copies of DNA molecules per cell; therefore, it is unlikely that random mutations induced by cytotoxic agents would affect a high number of genome copies. Accordingly, therapy-induced mutations were present at a low level. 4 Recently, Carew et al. 5 reported a high mtDNA mutation rate in leukocytes of patients with chronic lymphatic leukemia (CLL) after chemotherapy. In this study, the mtDNA sequences of primary CLL cells were compared to the Cambridge reference sequence. As expected, all patients displayed a variety of homoplasmic differences to the reference sequence of the mtDNA. No difference in the frequency of homoplasmic mutations was observed in the untreated and treated group. However, CLL cells with prior chemotherapy had a significant higher frequency of heteroplasmic mutations than those of untreated individuals. 5 In all cases, a high level of heteroplasmy between 30 and 70% was detected.
A similar observation was made in our laboratory in a patient with a relapse of acute lymphoblastic leukemia (ALL) (male, age 6 years). The mutation screening of the complete mtDNA revealed 19 acquired somatic heteroplasmies in peripheral blood mononucleoar cells (PBMC) 4 weeks after the onset of therapy (data not shown). The therapy regimen (BerlinFrankfurt-Mü nster (ALL-BFM) protocol) was identical to the one in the other 11 patients treated for ALL in our hospital, where we did not detect an increased number of somatic heteroplasmic mtDNA mutations in PBMC after chemotherapy (data not shown). Further evaluation of disease history and treatment revealed that the ALL patient described above had received a platelet concentrate 3 days prior to sampling of the patients blood. Unfortunately, at that time point, the patient was not available for additional investigations.
To test our hypothesis, that donor platelet contamination might have mimicked the induction of heteroplasmic mtDNA mutations in our patient, we investigated mtDNA mutations of PBMCs of patients prior and after single donor platelet infusion. White blood cells were isolated by selective lysis of red blood Figure 1 MtDNA analysis of a patient prior and post-infusion of platelets of a single donor. The first blood sample was collected at the same day before the transfusion of the platelet-concentrate, the second 1 h after the transfusion and a third blood sample was collected 2 weeks later. Samples from patients were collected after informed consent was given. Two regions of the mtDNA, containing parts of the COI (6747-7088) gene and D-loop (16098-16456), were amplified and sequenced as previously reported. 7 Sequence analysis of the first PCR fragment (a-d) showed a 7028T variation in the blood sample before the transfusion (a), and a 7028C variation in the donor platelets (b). The blood sample drawn 1 h after the injection represents both variants at 7028 (c). Sequence analysis of the second PCR fragment of the patients blood sample before the injection showed 16213G, 16273C, 16294T, 16296T and 16304C, and the donor platelets 16213A, 16273T, 16294C, 16296C and 16304T. Only the last three mutations are shown in the sequence (e-h). The blood sample drawn 1 h after the injection presented with the following mixtures 16213G/A, 16273C/T, 16294T/C, 16296T/C and 16304C/T (g). After 20 days, the sequence variants of the donor mtDNA disappeared (d, h).
